DK2608806T3 - Epstein-barr-virusvaccine - Google Patents
Epstein-barr-virusvaccineInfo
- Publication number
- DK2608806T3 DK2608806T3 DK11751867.0T DK11751867T DK2608806T3 DK 2608806 T3 DK2608806 T3 DK 2608806T3 DK 11751867 T DK11751867 T DK 11751867T DK 2608806 T3 DK2608806 T3 DK 2608806T3
- Authority
- DK
- Denmark
- Prior art keywords
- particle
- ebv
- vaccine
- epstein
- barr virus
- Prior art date
Links
- 241000701044 Human gammaherpesvirus 4 Species 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000002245 particle Substances 0.000 abstract 8
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 3
- 230000009466 transformation Effects 0.000 abstract 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000002101 lytic effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16223—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16251—Methods of production or purification of viral material
- C12N2710/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16261—Methods of inactivation or attenuation
- C12N2710/16262—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37702710P | 2010-08-25 | 2010-08-25 | |
| EP10008835 | 2010-08-25 | ||
| PCT/EP2011/064672 WO2012025603A1 (en) | 2010-08-25 | 2011-08-25 | An epstein-barr-virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2608806T3 true DK2608806T3 (da) | 2018-01-29 |
Family
ID=43478663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11751867.0T DK2608806T3 (da) | 2010-08-25 | 2011-08-25 | Epstein-barr-virusvaccine |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140227305A1 (da) |
| EP (1) | EP2608806B1 (da) |
| JP (1) | JP2013541507A (da) |
| CN (1) | CN103328003A (da) |
| DK (1) | DK2608806T3 (da) |
| ES (1) | ES2655535T3 (da) |
| WO (1) | WO2012025603A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9517261B2 (en) | 2011-12-30 | 2016-12-13 | Deutsches Krebsforschungszentrum | Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes |
| DE102012105193B4 (de) * | 2012-06-15 | 2014-04-03 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Stimulation der zellulären Immunantwort gegen das Epstein-Barr-Virus (EBV) |
| WO2014207708A2 (en) | 2013-06-28 | 2014-12-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| AU2015370479B2 (en) | 2014-12-23 | 2020-07-23 | Auckland Uniservices Limited | Amino acid and peptide conjugates and uses thereof |
| US10314906B2 (en) | 2015-03-18 | 2019-06-11 | University Of Massachusetts | Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease |
| WO2017145097A2 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| JP7517792B2 (ja) * | 2016-03-01 | 2024-07-17 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） | ヘルペスウイルス感染を処置するための手段及び方法 |
| EP3320917A1 (en) | 2016-11-10 | 2018-05-16 | Deutsches Krebsforschungszentrum | Improved ebv vaccine |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| US11806395B2 (en) | 2018-10-12 | 2023-11-07 | Deutsches Krebsforschungszentrum | Epstein-Barr virus-like particles with broadened antigenic spectrum |
| US20210398689A1 (en) * | 2020-06-23 | 2021-12-23 | Corsight.Ai | Autonomous mapping and monitoring potential infection events |
| CN111620955B (zh) * | 2020-07-01 | 2022-11-08 | 北京康爱瑞浩细胞技术有限公司 | 一种多靶位复合抗原及其应用 |
| WO2022073234A1 (zh) * | 2020-10-10 | 2022-04-14 | 中山大学肿瘤防治中心 | 一种抑制eb病毒的肽和编码该肽的dna及其应用 |
| US20240325539A1 (en) | 2020-10-20 | 2024-10-03 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods and compositions for treating epstein barr virus-associated cancer |
| WO2022084373A1 (en) | 2020-10-20 | 2022-04-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | METHOD FOR MANUFACTURING HEK293 CELL LINE, METHOD FOR MANUFACTURING EB-VLPs AND COMPOSITION COMPRISING SAID EB-VLPs |
| CN114657191B (zh) * | 2022-02-18 | 2023-08-01 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种EBNA3A截短mRNA相关疫苗及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5492418B2 (ja) * | 2005-11-18 | 2014-05-14 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法 |
| EP2065462A1 (en) * | 2007-11-27 | 2009-06-03 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens |
| EP2362901A1 (en) * | 2008-11-03 | 2011-09-07 | Ligocyte Pharmaceuticals, Inc. | Improved methods for isolating enveloped virus-based vlps free of infectious agents |
-
2011
- 2011-08-25 WO PCT/EP2011/064672 patent/WO2012025603A1/en active Application Filing
- 2011-08-25 JP JP2013525312A patent/JP2013541507A/ja active Pending
- 2011-08-25 EP EP11751867.0A patent/EP2608806B1/en active Active
- 2011-08-25 US US13/818,711 patent/US20140227305A1/en not_active Abandoned
- 2011-08-25 CN CN2011800511355A patent/CN103328003A/zh active Pending
- 2011-08-25 ES ES11751867.0T patent/ES2655535T3/es active Active
- 2011-08-25 DK DK11751867.0T patent/DK2608806T3/da active
-
2016
- 2016-03-22 US US15/077,477 patent/US10300129B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2608806A1 (en) | 2013-07-03 |
| US10300129B2 (en) | 2019-05-28 |
| EP2608806B1 (en) | 2017-10-25 |
| US20160296618A1 (en) | 2016-10-13 |
| WO2012025603A1 (en) | 2012-03-01 |
| JP2013541507A (ja) | 2013-11-14 |
| US20140227305A1 (en) | 2014-08-14 |
| CN103328003A (zh) | 2013-09-25 |
| ES2655535T3 (es) | 2018-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2608806T3 (da) | Epstein-barr-virusvaccine | |
| CY1122654T1 (el) | Ενωσεις για βελτιωμενη iiκη μεταγωγη | |
| CY1118138T1 (el) | Ιοσωματιο απελευθερουμενο μετα απο μολυνση κυτταρων θηλαστικων απο ανθρωπινο κυτταρομεγαλοϊο (hcmv) το οποιο περιεχει μια πρωτεϊνη συντηξης και χρηση αυτου | |
| MX2015005505A (es) | Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano. | |
| EP2614140B8 (en) | Mdck-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells | |
| NZ712943A (en) | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels | |
| WO2011109833A3 (en) | Induced dendritic cell compositions and uses thereof | |
| WO2013142324A8 (en) | Neutralizing antibodies to hiv-1 and their use | |
| EP2660917A4 (en) | METAL SUPPORTED SOLID OXIDE FUEL CELL UNIT, PROCESS FOR PREPARING AND STACKING SOLID OXIDE FUEL CELLS USING THE UNIT CELL | |
| MX2010003713A (es) | Vacunas de citomegalovirus y metodos de produccion. | |
| IL251338B (en) | Plant cells and extracts containing virus-like particles containing chimeric viral proteins and compounds thereof | |
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| MX2014015496A (es) | Complejos de proteinas de citomegalovirus. | |
| MX359903B (es) | Proteínas estructurales de una mutación del parvovirus como vacunas. | |
| PH12015500499A1 (en) | Recombinant measles virus expressing chikungunya virus polypeptides and their applications | |
| WO2011137354A3 (en) | Delivery proteins | |
| WO2013096866A3 (en) | Processes using vlps with capsids resistant to hydrolases | |
| CA2863981A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
| WO2010118205A3 (en) | Production of an intact virus in a mammalian (non-host) cell system using a secondary non-host viral construct | |
| WO2011092593A3 (en) | Hiv-1 neutralizing antibodies and uses thereof | |
| WO2010118188A3 (en) | Production of an intact virus in a non-host cell system using a secondary host viral construct | |
| NZ611531A (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
| WO2011112601A3 (en) | Continuous flow bioreactor for magnetically stabilized three-dimensional tissue culture | |
| HK1210475A1 (en) | Herpes simplex virus vaccine | |
| WO2011057254A3 (en) | Simian adenoviral vector-based vaccines |